OBJECTIVES: Fecal microbiota transplantation (FMT) is arguably the most effective treatment for recurrent Clostridioides difficile infection (rCDI). Clinical reports on pediatric FMT have not systematically evaluated microbiome restoration in patients with co-morbidities. Here, we determined whether FMT recipient age and underlying co-morbidity influenced clinical outcomes and microbiome restoration when treated from shared fecal donor sources. METHODS: Eighteen rCDI patients participating in a single-center, open-label prospective cohort study received fecal preparation from a self-designated (single case) or two universal donors. Twelve age-matched healthy children and four pediatric ulcerative colitis (UC) cases from an independent serial FMT trial, but with a shared fecal donor were examined as controls for microbiome restoration using 16S rRNA gene sequencing of longitudinal fecal specimens. RESULTS: FMT was significantly more effective in rCDI recipients without underlying chronic co-morbidities where fecal microbiome composition in post-transplant responders was restored to levels of healthy children. Microbiome reconstitution was not associated with symptomatic resolution in some rCDI patients who had co-morbidities. Significant elevation in Bacteroidaceae, Bifidobacteriaceae, Lachnospiraceae, Ruminococcaceae, and Erysipelotrichaceae was consistently observed in pediatric rCDI responders, while Enterobacteriaceae decreased, correlating with augmented complex carbohydrate degradation capacity. CONCLUSION: Recipient background disease was a significant risk factor influencing FMT outcomes. Special attention should be taken when considering FMT for pediatric rCDI patients with underlying co-morbidities.
OBJECTIVES: Fecal microbiota transplantation (FMT) is arguably the most effective treatment for recurrent Clostridioides difficile infection (rCDI). Clinical reports on pediatric FMT have not systematically evaluated microbiome restoration in patients with co-morbidities. Here, we determined whether FMT recipient age and underlying co-morbidity influenced clinical outcomes and microbiome restoration when treated from shared fecal donor sources. METHODS: Eighteen rCDI patients participating in a single-center, open-label prospective cohort study received fecal preparation from a self-designated (single case) or two universal donors. Twelve age-matched healthy children and four pediatric ulcerative colitis (UC) cases from an independent serial FMT trial, but with a shared fecal donor were examined as controls for microbiome restoration using 16S rRNA gene sequencing of longitudinal fecal specimens. RESULTS: FMT was significantly more effective in rCDI recipients without underlying chronic co-morbidities where fecal microbiome composition in post-transplant responders was restored to levels of healthy children. Microbiome reconstitution was not associated with symptomatic resolution in some rCDI patients who had co-morbidities. Significant elevation in Bacteroidaceae, Bifidobacteriaceae, Lachnospiraceae, Ruminococcaceae, and Erysipelotrichaceae was consistently observed in pediatric rCDI responders, while Enterobacteriaceae decreased, correlating with augmented complex carbohydrate degradation capacity. CONCLUSION: Recipient background disease was a significant risk factor influencing FMT outcomes. Special attention should be taken when considering FMT for pediatric rCDI patients with underlying co-morbidities.
Authors: Jonathan D Crews; Hoonmo L Koo; Zhi-Dong Jiang; Jeffrey R Starke; Herbert L DuPont Journal: Pediatr Infect Dis J Date: 2014-09 Impact factor: 2.129
Authors: Gavin M Douglas; Vincent J Maffei; Jesse R Zaneveld; Svetlana N Yurgel; James R Brown; Christopher M Taylor; Curtis Huttenhower; Morgan G I Langille Journal: Nat Biotechnol Date: 2020-06 Impact factor: 54.908
Authors: Zachariah DeFilipp; Patricia P Bloom; Mariam Torres Soto; Michael K Mansour; Mohamad R A Sater; Miriam H Huntley; Sarah Turbett; Raymond T Chung; Yi-Bin Chen; Elizabeth L Hohmann Journal: N Engl J Med Date: 2019-10-30 Impact factor: 91.245
Authors: José Luís Fachi; Jaqueline de Souza Felipe; Laís Passariello Pral; Bruna Karadi da Silva; Renan Oliveira Corrêa; Mirella Cristiny Pereira de Andrade; Denise Morais da Fonseca; Paulo José Basso; Niels Olsen Saraiva Câmara; Éricka Lorenna de Sales E Souza; Flaviano Dos Santos Martins; Suzana Eiko Sato Guima; Andrew Maltez Thomas; João Carlos Setubal; Yuli Thamires Magalhães; Fábio Luis Forti; Thamiris Candreva; Hosana Gomes Rodrigues; Marcelo Bispo de Jesus; Sílvio Roberto Consonni; Alessandro Dos Santos Farias; Patrick Varga-Weisz; Marco Aurélio Ramirez Vinolo Journal: Cell Rep Date: 2019-04-16 Impact factor: 9.423
Authors: Sahil Khanna; Yoshiki Vazquez-Baeza; Antonio González; Sophie Weiss; Bradley Schmidt; David A Muñiz-Pedrogo; John F Rainey; Patricia Kammer; Heidi Nelson; Michael Sadowsky; Alexander Khoruts; Stefan L Farrugia; Rob Knight; Darrell S Pardi; Purna C Kashyap Journal: Microbiome Date: 2017-05-15 Impact factor: 14.650
Authors: Ramandeep Singh; Pieter F de Groot; Suzanne E Geerlings; Caspar J Hodiamont; Clara Belzer; Ineke J M Ten Berge; Willem M de Vos; Frederike J Bemelman; Max Nieuwdorp Journal: BMC Res Notes Date: 2018-03-22
Authors: Matthew T Sorbara; Krista Dubin; Eric R Littmann; Thomas U Moody; Emily Fontana; Ruth Seok; Ingrid M Leiner; Ying Taur; Jonathan U Peled; Marcel R M van den Brink; Yael Litvak; Andreas J Bäumler; Jean-Luc Chaubard; Amanda J Pickard; Justin R Cross; Eric G Pamer Journal: J Exp Med Date: 2018-12-18 Impact factor: 14.307
Authors: Jacob M Parnell; Irtiqa Fazili; Sarah C Bloch; D Borden Lacy; Valeria A Garcia-Lopez; Rachel Bernard; Eric P Skaar; Kathryn M Edwards; Maribeth R Nicholson Journal: J Pediatr Gastroenterol Nutr Date: 2021-03-01 Impact factor: 3.288